Novo Nordisk's U.S.-listed and domestic shares rose Wednesday after analysts from UBS upgraded the Danish drugmaker's stock ...

At least four analysts weighed in on the prospects for Europe’s second-largest company, Novo Nordisk, after the Danish ...

Novo Nordisk shares fell nearly 30% in the fourth quarter on disappointing clinical trial data, and other concerns. Bank of ...

Eli Lilly's Tirzepatide Outshines Novo Nordisk's Semaglutide, Yet Brand Recognition Remains Strong for Novo's Products ...

Putting tariffs on Denmark unless it cedes the island of Greenland could hurt access to a few key products, including popular ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

While 80% of companies cover diabetes drugs like Novo Nordisk's (NVO) Ozempic and Eli Lilly's (LLY) Mounjaro, the number of those covering them for weight loss is at 45%. The executives were comprised ...

A range of GLP-1 weight loss drugs are currently on the market. What are they, what do they do, and where are they available?

As India steps into 2025, breakthrough weight-loss drugs, economic shifts, and global trends shape the road to a Viksit ...

It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...

Here are some of the drugs that are predicted to become blockbusters in the next few years, according to Clarivate's latest ...